Abstract
We studied 94 clinically heterogeneous chronic myeloid leukemia (CML) patients and found that the duration of treatment with interferon-alpha (IFN-alpha) prior to imatinib therapy may not improve response to imatinib for patients in chronic phase but a shorter period between CML diagnosis and the initiation of imatinib is predictive for a better molecular response to therapy (p<0.05).
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Benzamides
-
Drug Administration Schedule
-
Female
-
Humans
-
Imatinib Mesylate
-
Interferon-alpha / administration & dosage
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Male
-
Middle Aged
-
Piperazines / therapeutic use*
-
Pyrimidines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Benzamides
-
Interferon-alpha
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate